Explore the pivotal role of ALDH1A3 in breast cancer progression highlighted in a recent study, reinforcing Theranib’s mission to advance ALDH1A3-targeted therapies.
Theranib at OBIO Investment Summit 2026
Thrilled to share that Theranib has been invited to pitch at OBIO in Toronto (Feb 3–6) 🇨🇦It’s an exciting opportunity to present our vision and progress to a community that’s shaping the future of biotech innovation.If you’re attending and interested in…
Theranib at BIOTECanada Coast to Coast Competition
Theranib secured a coveted spot to pitch at the BIOTECanada Coast to Coast Competition at BIO 2025 in Boston.This is an incredible opportunity to showcase our innovation on an international stage, and connect with global leaders in biotech, pharma, and investment….
Theranib at BIO 2025
Theranib will be attending the BIO International Convention, that is the premier global event for biotechnology and life sciences. Our team will be actively engaging with peers to explore scientific collaborations and strategic partnerships, to advance innovation in oncology. We look…